Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
Add more filters










Publication year range
1.
Lancet ; 358(9293): 1613-4, 2001 Nov 10.
Article in English | MEDLINE | ID: mdl-11716893

ABSTRACT

Liquorice consumption has been shown to substantially reduce serum testosterone concentration. An explanation for this result was that the active component in liquorice (glycyrrhizic acid) interfered with 17 beta-hydroxysteroid deyhydrogenase, which has been shown in vitro to catalyse the conversion of androstenedione to testosterone. We twice attempted to replicate this effect of liquorice but could not. We identified differences between our methods and those of the previous study and possible statistical anomalies (including inappropriate use of statistical tests) in the earlier report.


Subject(s)
Glycyrrhiza , Hydrocortisone/blood , Saliva/chemistry , Testosterone/metabolism , Adult , Female , Humans , Male
2.
J Biol Chem ; 276(49): 46436-44, 2001 Dec 07.
Article in English | MEDLINE | ID: mdl-11564730

ABSTRACT

Epidermal growth factor (EGF) stimulates gastric acid secretion and H(+)/K(+)-ATPase alpha-subunit gene expression. Because EGF activates the serine-threonine protein kinase Akt, we explored the role of Akt in gastric acid secretion. Akt phosphorylation and activation were measured by kinase assays and by Western blots with an anti-phospho-Akt antibody, using lysates of purified (>95%) canine gastric parietal cells in primary culture. EGF induced Akt phosphorylation and activation, whereas carbachol had no effect. LY294002, an inhibitor of phosphoinositide 3-kinase, completely blocked EGF induction of Akt phosphorylation, whereas the MEK1 inhibitor PD98059 and the protein kinase C inhibitor GF109203X had no effect. We examined the role of Akt in H(+)/K(+)-ATPase gene expression by Northern blotting using a canine H(+)/K(+)-ATPase alpha-subunit cDNA probe. The parietal cells were transduced with a multiplicity of infection of 100 of the adenoviral vector Ad.Myr-Akt, which overexpresses a constitutively active Akt gene, or with the control vector Ad.CMV-beta-gal, which expresses beta-galactosidase. Ad.Myr-Akt induced H(+)/K(+)-ATPase alpha-subunit gene expression 3-fold, whereas it failed to stimulate the gene cyclooxygenase-2, which was potently induced by carbachol in the same parietal cells. Ad.Myr-Akt induced aminopyrine uptake 4-fold, and it potentiated the stimulatory action of carbachol 3-fold. In contrast, Ad.Myr-Akt failed to induce changes in either parietal cell actin content, measured by Western blots with an anti-actin antibody or in the organization of the actin cellular cytoskeleton, visualized by fluorescein phalloidin staining and confocal microscopy. Transduction of the parietal cells with a multiplicity of infection of 100 of the adenoviral vector Ad.dom.neg.Akt, which overexpresses an inhibitor of Akt, blocked the stimulatory effect of EGF on both aminopyrine uptake and H(+)/K(+)-ATPase production, measured by Western blots with an anti-H(+)/K(+)-ATPase alpha-subunit antibody. Thus, EGF induces a cascade of events in the parietal cells that results in the activation of Akt. The functional role of Akt appears to be stimulation of gastric acid secretion through induction of H(+)/K(+)-ATPase expression.


Subject(s)
Gastric Acid/metabolism , Gene Expression Regulation, Enzymologic/physiology , H(+)-K(+)-Exchanging ATPase/genetics , Parietal Cells, Gastric/enzymology , Protein Serine-Threonine Kinases , Proto-Oncogene Proteins/physiology , Cells, Cultured , Epidermal Growth Factor/pharmacology , Parietal Cells, Gastric/drug effects , Parietal Cells, Gastric/metabolism , Phosphorylation , Proto-Oncogene Proteins c-akt , RNA, Messenger/genetics
3.
Am J Physiol Heart Circ Physiol ; 280(3): H1415-21, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11179092

ABSTRACT

Cultured rat cardiac myocytes and A7r5 cells were transfected with an adenoviral vector used earlier for in vivo expression of functional alpha(2)-isoform of the catalytic subunit of rat Na(+)-K(+)-ATPase. Expressions of truncated forms of alpha(2), but little or no intact alpha(2), were detected, suggesting the rapid degradation of alpha(2) in these cultured cells. In neonatal myocytes normally containing the alpha(1)- and the alpha(3)-isoforms, expression of the alpha(2)-fragment led to 1) a significant decrease in the level of endogenous alpha(1)-protein and a modest decrease in alpha(3)-protein, 2) decreases in mRNAs of alpha(1) and alpha(3), 3) decrease in Na(+)-K(+)-ATPase function measured as ouabain-sensitive Rb(+) uptake, 4) increase in intracellular Ca(2+) concentration similar to that induced by ouabain, and 5) eventual loss of cell viability. These findings indicate that the alpha(2)-fragment downregulates endogenous Na(+)-K(+)- ATPase most likely by dominant negative interference either with folding and/or assembly of the predominant housekeeping alpha(1)-isoform or with signal transducing function of the enzyme. Demonstration of rise in intracellular Ca(2+) resulting from alpha(1)-downregulation 1) does not support the previously suggested special roles of less abundant alpha(2)- and alpha(3)-isoforms in the regulation of cardiac Ca(2+), 2) lends indirect support to proposals that observed decrease in total Na(+)-K(+)-ATPase of the failing heart may be a mechanism to compensate for impaired cardiac contractility, and 3) suggests the potential therapeutic utility of dominant negative inhibition of Na(+)-K(+)-ATPase.


Subject(s)
Adenoviridae/genetics , Gene Expression Regulation, Enzymologic , Muscle Fibers, Skeletal/enzymology , Myocardium/enzymology , Sodium-Potassium-Exchanging ATPase/genetics , Animals , Animals, Newborn , Cells, Cultured , Enzyme Inhibitors/pharmacology , Gene Expression Regulation, Viral , Muscle Fibers, Skeletal/cytology , Myocardium/cytology , Ouabain/pharmacology , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Rubidium Radioisotopes , Sodium-Potassium-Exchanging ATPase/antagonists & inhibitors , Sodium-Potassium-Exchanging ATPase/metabolism , Transfection
4.
Am J Physiol Gastrointest Liver Physiol ; 280(2): G298-307, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11208554

ABSTRACT

Gastrin (G17) has a CCK-B receptor-mediated growth-promoting effect on the AR42J rat acinar cell line. We examined whether G17 inhibits apoptosis induced by serum withdrawal of AR42J cells and CHO-K1 cells stably expressing CCK-B receptors (CHO-K1/CCK-B cells). Cellular apoptosis was measured by flow cytometry and the terminal deoxynucleotidyltransferase-mediated dUTP-FITC nick end-labeling method. Serum withdrawal induced AR42J and CHO-K1/CCK-B cell apoptosis. Addition of 10 nM G17 reversed these effects. We examined the action of G17 (10 nM) on phosphorylation and activation of protein kinase B/Akt, a kinase known to promote cell survival. Akt phosphorylation and activation were measured by kinase assays and Western blots with an anti-phospho-Akt antibody. G17 stimulated Akt phosphorylation and activation. G17 induction of Akt phosphorylation was inhibited by the phosphoinositide 3-kinase (PI 3-kinase) inhibitors LY-294002 (10 microM) and wortmannin (200 nM) but not by the mitogen-activated protein kinase kinase 1 inhibitor PD-98059 (50 microM). To study the role of p38 kinase in G17 signaling to Akt, we examined the effect of G17 on p38 kinase activation and phosphorylation using kinase assays and Western blots with an anti-phospho-p38 kinase antibody. G17 induced p38 kinase activity at doses and with kinetics similar to those observed for Akt induction. The p38 kinase inhibitor SB-203580 inhibited G17 induction of Akt phosphorylation and activation at a concentration (10 microM) 10-fold higher than necessary to block p38 kinase (1 microM), suggesting the possible involvement of kinase activities other than p38 kinase. Transduction of AR42J cells with the adenoviral vector Adeno-dn Akt, which overexpresses an inhibitor of Akt, reversed the antiapoptotic action of G17. In conclusion, G17 promotes AR42J cell survival through the induction of Akt via PI 3-kinase and SB-203580-sensitive kinase activities.


Subject(s)
Apoptosis/drug effects , Gastrins/pharmacology , Protein Serine-Threonine Kinases , Animals , CHO Cells , Cell Line , Cricetinae , DNA Fragmentation , Enzyme Activation/physiology , In Situ Nick-End Labeling , Mitogen-Activated Protein Kinases/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Phosphorylation , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins/physiology , Proto-Oncogene Proteins c-akt , Rats , Receptor, Cholecystokinin B , Receptors, Cholecystokinin/physiology , Signal Transduction/drug effects , Signal Transduction/physiology , p38 Mitogen-Activated Protein Kinases
6.
JAMA ; 278(22): 2000-7, 1997 Dec 10.
Article in English | MEDLINE | ID: mdl-9396663

ABSTRACT

Immunization is undergoing important changes, with improved vaccines replacing less immunogenic or less safe vaccines, new vaccines for common diseases such as chickenpox and hepatitis A infection, and improved immunization schedules. Immunization is also being transformed by basic work in molecular medicine. Vaccines made of DNA are being developed as a form of gene therapy that use the patient's own cellular machinery to make foreign proteins that stimulate an immune response. Currently immunization is used to protect patients prior to exposure to an infectious agent or during the incubation phase after exposure, but before disease has occurred. New technologies are being investigated to induce the immune system to fight infections that have already produced chronic disease such as acquired immunodeficiency syndrome and chronic hepatitis B virus infection.


Subject(s)
Immunization , Vaccines , Humans , Immunization/adverse effects , Immunization/methods , Immunization/trends , Immunocompromised Host , Travel , Vaccines/adverse effects , Vaccines/immunology , Vaccines, DNA
7.
FEBS Lett ; 405(1): 5-10, 1997 Mar 17.
Article in English | MEDLINE | ID: mdl-9094414

ABSTRACT

These are the first experiments to study the effect of in vivo expression of the Na/K-ATPase alpha2 subunit which serves as a receptor for cardiac glycosides. The alpha2 subunit is not normally expressed in rat liver, so hepatocytes which lack endogenous alpha2 protein are a logical first target to study the effects of alpha2 expression on membrane Na/K-ATPase activity. At 3 days after alpha2 adenovirus vector infusion, Wistar rat livers contained alpha2 DNA, alpha2 mRNA, and alpha2 protein. Rat liver membrane ouabain binding activity and the sensitivity of Na/K-ATPase activity to ouabain significantly increased. Total membrane Na/K-ATPase was regulated at a constant level while expressed alpha2 activity represented 10% of the total active Na/K-ATPase sites in alpha2 transduced rat liver. These studies are the first to establish a paradigm in which an endogenous drug receptor is expressed to alter cellular pharmacologic sensitivity.


Subject(s)
Adenoviruses, Human/genetics , Genetic Vectors , Liver/metabolism , Ouabain/metabolism , Sodium-Potassium-Exchanging ATPase/metabolism , Animals , Cell Line, Transformed , Cell Membrane/metabolism , DNA, Viral/analysis , HeLa Cells , Humans , Immunoblotting , Infusions, Intravenous , Injections, Intravenous , Ouabain/pharmacology , RNA, Viral/analysis , Rabbits , Rats , Rats, Wistar , Receptors, Drug/metabolism , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Sodium-Potassium-Exchanging ATPase/genetics , Transformation, Genetic
8.
Gene Ther ; 3(5): 381-8, 1996 May.
Article in English | MEDLINE | ID: mdl-9156798

ABSTRACT

Recombinant adenoviral vectors are useful for the in vivo expression of genes in hepatocytes. Adenoviral vectors deleted in E1a, E1b, and E3b were constructed and used to study in vivo expression of the major human bilirubin UDP-glucuronosyltransferase isoform (HUG Br1) under the transcriptional control of the cytomegalovirus (CMV) immediate-early promoter-enhancer (H5.010CMV hugBr1). As a control, a recombinant adenoviral vector containing the beta-galactosidase reporter gene driven by the CMV promoter-enhancer was employed (H5. 010CMVlacZ). Recombinant virus was expanded following exposure to E1 transcomplementing (293) cells and concentrated to t titer of approximately 10(13) particles per milliliter. A rat model for Crigler-Najjar syndrome type I deficient in HUG Br1 (ie the Gunn rat) was injected with 5 X 10(9) plaque-forming units (p.f.u.) via the portal vein of either H5.010CMVhugBr1 or H5. 010CMVlacZ. Rats from each set were killed at 3 days, 11 days and 22 days after infusion. Liver total cellular DNA, RNA and protein were analyzed for the transgene and the transgene product at the specified times. Analysis of livers by Southern blot hybridization demonstrates sequence-specific hybridization to adenoviral vector DNA, and Northern blot hybridization demonstrates sequence-specific hybridization to transgene-derived RNA. DNA levels peak at approximately one copy number at 3 days and decline over 22 days. RNA and Western blot analyses demonstrate overexpression of message and protein at 3 days, declining over 22 days. In virto functional assay for bilirubin glucuronosyl-transferase activity demonstrates overexpression of bilirubin UDP-glucurosyltransferase function. In situ hybridization of frozen sections to detect expressed mRNA using beta-galactosidasederived 35S-labeled riboprobes demonstrates adenovirus-derived transgene expression in hepatocytes. Significant drops in serum bilirubin levels were noted following expression of HUG Br1 but not beta-galactosidase. The drop in serum bilirubin correlates with the appearance of bilirubin glucuronides in bile. In summary, recombinant adenoviral vectors were used to demonstrate in vivo complementation of the genetic defect in Gunn rat livers with the HUG Br1 cDNA leading to a resolution of hyperbilirubinemia lasting approximately 7 weeks. These studies suggest that delivery of the HUG Br1 cDNA might provide a reasonable therapeutic benefit for Crigler-Najjar syndrome type I patients, as safe and efficacious gene delivery systems are developed.


Subject(s)
Bilirubin/metabolism , Crigler-Najjar Syndrome/therapy , Genetic Therapy , Glucuronosyltransferase/genetics , Hyperbilirubinemia/therapy , Adenoviridae , Animals , Crigler-Najjar Syndrome/genetics , Crigler-Najjar Syndrome/metabolism , Gene Expression , Gene Transfer Techniques , Genetic Vectors , Glucuronosyltransferase/deficiency , Humans , In Situ Hybridization , Rats , Rats, Gunn
10.
Biochem Pharmacol ; 51(4): 483-8, 1996 Feb 23.
Article in English | MEDLINE | ID: mdl-8619894

ABSTRACT

The initial identification of traditionally hepatic enzymes expressed in the gut has led to the hypothesis that the gut may function as a metabolic organ. The UDP glucuronosyltransferases (UDP-GTs) play an important role as phase II metabolizing enzymes. Previously members of this family have been identified in the gut by non-isoform specific immunoreactivity, and a small amount of bilirubin glucuronosyltransferase activity was detected in the colon. Recent reports of gut transplantation to reverse the metabolic defect in Gunn rats raised further interest in the expression and distribution of human bilirubin (UDP-GTs (HUG Br 1 and HUG Br 2) in the human alimentary tract. The availability of molecular genetic probes for HUG Br 1 and HUG Br 2 permits the screening of the alimentary tract for the presence of isoform specific message. RNA samples extracted from pinch biopsy specimens of buccal mucosa, esophagus, stomach body, antrum, duodenum, and colon were analyzed for expression of HUG Br 1 and HUG Br 2. HUG Br 1 hybridization was detected in duodenum > colon, whereas HUG Br2 hybridization was detected in duodenum > esophagus > colon. Immunoreactivity data confirmed the presence of HUG Br 1 protein at low levels in the duodenum, whereas the less abundant HUG Br 2 protein was below the limits of detection of isoform specific anti-peptide antibodies. Bilirubin specific reactivity was demonstrated in duodenal samples but not antrum samples, consistent with the molecular genetic data. The presence of functional bilirubin UDP-GT isoforms in human alimentary tract supports the notion that the gut may function as a metabolic organ and may have diagnostic and therapeutic implications for disorders of bilirubin metabolism.


Subject(s)
Digestive System/enzymology , Glucuronosyltransferase/analysis , Glucuronosyltransferase/biosynthesis , Microsomes, Liver/enzymology , Adult , Amino Acid Sequence , Animals , Base Sequence , Biopsy , Blotting, Western , Cell Line , Chlorocebus aethiops , DNA Primers , Female , Humans , Intestinal Mucosa/enzymology , Isoenzymes/analysis , Isoenzymes/biosynthesis , Male , Molecular Sequence Data , Mouth Mucosa/enzymology , Organ Specificity , Rats , Rats, Gunn , Recombinant Proteins/analysis , Recombinant Proteins/biosynthesis , Reference Values , Transfection
12.
Science ; 271(5246): 223b-4b, 1996 Jan 12.
Article in English | MEDLINE | ID: mdl-17793399
15.
Gene Ther ; 2(3): 203-8, 1995 May.
Article in English | MEDLINE | ID: mdl-7614251

ABSTRACT

Crigler-Najjar syndrome type I (CN-I) is a congenital hepatic metabolic deficiency in bilirubin UDP-glucuronosyltransferase activity which leads to profound jaundice and death from kernicterus. UGT1, the gene locus coding for multiple glucuronosyltransferase isoforms, has been well characterized and the cDNA for the most active form, HUG Br1, has been cloned. Recent advances in liver directed gene transfer suggest that this disease could be treated through gene therapy. As an initial step to correct the genetic defect in Crigler-Najjar type I, recombinant retroviruses were used to transduce an HUG Br1 gene into hepatocytes of a rat model of CN-I and CN-I fibroblasts. The retroviral vector gagCMVBA HUG Br1 was constructed and helper-free amphotrophic virus was isolated and used to transfer bilirubin UDP-glucuronosyltransferase activity to genetically deficient cells. The efficiency of transduction as measured by Southern blot analysis of integrated proviral sequences in DNA of recipient cells ranged from 5 to 100%. HUG Br1 gene expression was documented by blot hybridization analysis of total cellular RNA, immunotransblot analysis using a rabbit polyclonal antipeptide HUG Br1 antibody, and lysate enzymatic assay of bilirubin UDP-glucuronosyltransferase activity. HUG Br1 gene transfer was definitively demonstrated by four independent modalities following HUG Br1 retroviral transduction.


Subject(s)
Crigler-Najjar Syndrome/genetics , Fibroblasts/enzymology , Gene Transfer Techniques , Glucuronosyltransferase/genetics , Liver/enzymology , Amino Acid Sequence , Animals , Base Sequence , Bilirubin/metabolism , Crigler-Najjar Syndrome/enzymology , Gene Expression , Genetic Vectors/genetics , Glucuronosyltransferase/biosynthesis , Glucuronosyltransferase/metabolism , Humans , Liver/cytology , Molecular Sequence Data , Peptide Fragments/chemical synthesis , Peptide Fragments/immunology , Proviruses/genetics , Rats , Rats, Gunn , Retroviridae/genetics
16.
J Viral Hepat ; 2(5): 235-41, 1995.
Article in English | MEDLINE | ID: mdl-8745315

ABSTRACT

Hepatitis C virus (HCV) is a major healthproblem with a prevalence of 1% in the United States population, and a significant percentage of infected patients progress to chronic liver disease and cirrhosis. Interferon therapy has demonstrated that the immune system can be modulated to alter the acute course of the disease, but long-term treatments remain elusive. Prevention of hepatitis C infection is therefore an important strategy to mitigate the impact of this disease. Initial attempts at vaccination have focused on recombinant envelope vaccines, which have shown an ability to protect against very low titre challenges of HCV in chimps. The need for vaccines capable of protecting against higher titre challenges has led to the search for alternative vaccine strategies. The most highly conserved structural protein in the HCV genome is the core protein, and vaccine strategies targeting the core protein have been proposed to increase vaccine efficacy. The variability of HCV core sequences and genotypes in the Ann Arbor patient population are not known, and the present study was undertaken to assess the theoretical feasibility of developing a HCV core vaccine by excluding promiscuous core (C) gene variability as a mechanism of vaccine failure. Results of nucleotide and deduced amino acid sequence analysis from 13 of 14 patients studied reveal a 93% nucleotide and 96.4% amino acid core sequence homology in the C gene regions studied. Genotype analysis revealed four of 14 to be type 1a and nine of 14 to be type 1b with one infection not being sufficiently characterized to determine genotype. These results demonstrate a sufficiently high degree of conservation of HCV core sequences in our patient population to permit design of a vaccine directed against core protein.


Subject(s)
Viral Core Proteins/genetics , Amino Acid Sequence , Base Sequence , Genetic Variation , Hepatitis C Antibodies/analysis , Immunoblotting , Molecular Sequence Data , Polymerase Chain Reaction , Sequence Homology, Amino Acid , Sequence Homology, Nucleic Acid , Viral Core Proteins/immunology
17.
Viral Immunol ; 8(2): 109-19, 1995.
Article in English | MEDLINE | ID: mdl-8825296

ABSTRACT

Hepatitis C virus (HCV) produces chronic persistent liver infection in 1-2% of the U.S. population and is the leading cause of end stage liver disease in patients presenting for liver transplantation at our center. Efforts to cure persistent HCV infection are frequently unsuccessful, so the development of a HCV vaccine is a high priority. HCV envelope proteins are hypervariable so production of a recombinant surface antigen vaccine such as is available for hepatitis B is not likely to confer widespread, high level protective immunity. As the most highly conserved structural protein in the HCV genome, the core protein is one reasonable target for vaccine production. Presented here are data on the manufacture of recombinant core protein containing partial carboxy terminus deletions in an effort to increase the efficiency of core expression. The maltose binding protein (MBP) and glutathione S-transferase (GST) protein prokaryotic expression systems were used to study two different constructs, expressing the first 140 and 163 amino acids of the core region. Deletion of the 23 amino acids (aa) from aa141-163 led to a marked increase in the efficiency of protein production from < 1 to 3-4 mg/liter for both systems studied. Protein purification was accomplished using affinity chromatography (MBP) or inclusion body isolation (GST) as determined by SDS-PAGE gels and immunotransblot with HCV core protein-specific monoclonal antibody. Finally, the immune response to recombinant protein was assessed in BALB/c mice using a MBP HCV core fusion protein and an ELISA developed using GST HCV core protein as a target. In all mice of this strain, serum anti-HCV core antibody titer increased to 10(-4), two logs above background, following immunization in conjunction with Freund's complete adjuvant. These results represent an encouraging first step toward production of a core protein vaccine. Recombinant core protein is a useful tool to study the immune response to core protein and may be useful to further study the epidemiology and biology of the HCV virus.


Subject(s)
Hepacivirus/immunology , Hepatitis C Antibodies/immunology , Hepatitis C/immunology , Viral Core Proteins/immunology , 3T3 Cells , Amino Acid Sequence , Animals , Base Sequence , DNA, Viral/genetics , Disease Models, Animal , Escherichia coli , Gene Expression Regulation, Viral/genetics , Glutathione Transferase/genetics , Hepacivirus/chemistry , Hepacivirus/genetics , Hepatitis C/blood , Hepatitis C/virology , Hepatitis C Antibodies/blood , Humans , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Molecular Sequence Data , Prokaryotic Cells , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , T-Lymphocytes, Cytotoxic/immunology , Viral Core Proteins/chemistry , Viral Core Proteins/genetics
19.
Somat Cell Mol Genet ; 18(6): 559-69, 1992 Nov.
Article in English | MEDLINE | ID: mdl-1287854

ABSTRACT

Antisense oligonucleotides efficiently inhibit gene expression in vitro; however, the successful therapeutic application of this technology in vivo will require the development of improved delivery systems. In this report we describe a technique that efficiently delivers antisense oligonucleotides into cells using molecular conjugates. This technique, which was initially developed for the delivery of eukaryotic genes, is based on the construction of DNA-protein complexes that are recognized by the liver-specific asialoglycoprotein receptor. Binding of poly(L-lysine)-asialoorosomucoid (AsOR) protein conjugates with phosphorothioate antisense oligonucleotides to chloramphenicol acetyltransferase (CAT) led to the formation of 50- to 150-nm toroids. Exposure of the antisense molecular complexes (3 microM oligonucleotide) to NIH 3T3 cells genetically modified to express both the AsOR receptor and CAT, inhibited CAT expression by 54%, which was completely blocked by excess AsOR. Equivalent inhibition of CAT activity with purified oligonucleotide alone was observed at a 30 microM concentration. Furthermore, examination of the cells using indirect immunofluorescence for the presence of CAT protein showed 28% of cells exposed to the molecular conjugates lacked any detectable CAT enzyme. Cells exposed to oligonucleotide alone showed a highly variable staining pattern, and only a few of the cells were completely void of CAT protein. Together these data demonstrate that molecular conjugates provide a highly specific and efficient system for the delivery of antisense oligonucleotides.


Subject(s)
Oligonucleotides, Antisense/administration & dosage , 3T3 Cells , Animals , Asialoglycoprotein Receptor , Asialoglycoproteins , Base Sequence , Cell Line , Chloramphenicol O-Acetyltransferase/genetics , Chloramphenicol O-Acetyltransferase/metabolism , DNA/chemistry , DNA/genetics , Drug Carriers , Immunologic Techniques , Mice , Microscopy, Electron , Molecular Sequence Data , Oligonucleotides, Antisense/genetics , Orosomucoid/analogs & derivatives , Polylysine/analogs & derivatives , Receptors, Immunologic/genetics , Receptors, Immunologic/metabolism , Thionucleotides/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...